Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Welcome
Go
Free Newsletter Sign Up

Biogen’s FDA Victory Changes the Game for Alzheimer’s Drugs (1)

June 8, 2021, 4:41 PM

Biogen Inc. took a colossal risk in late 2019. It revived an Alzheimer’s disease drug it had left for dead earlier that year after it appeared to fail two large clinical trials.

The company wasn’t ready to take no for an answer. Biogen had poured years of effort into developing the therapy, then called aducanumab, and was counting on it as its next big therapeutic advance.

After months of controversy, Biogen’s bet paid off in spectacular fashion Monday when the U.S. Food and Drug Administration granted the treatment its approval, making it the first new Alzheimer’s drug in almost 20 ...